» Articles » PMID: 35308082

Peripheral Inflammatory Cytokines and Motor Symptoms in Persons with Parkinson's Disease

Overview
Date 2022 Mar 21
PMID 35308082
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Many of the motor symptoms of Parkinson's disease (PD) impact quality of life and are not fully ameliorated by current pharmacological and surgical treatments. A better understanding of the pathophysiology underlying these symptoms is needed. Previous research has suggested that inflammation may play a significant role in PD pathophysiology and progression, but there is limited research exploring how inflammation directly relates to motor symptoms in PD. Thus, the purpose of this study was to evaluate associations between peripheral immune inflammatory markers and motor symptoms of PD, specifically, tremor, bradykinesia, and postural and gait instability. We hypothesized that peripheral inflammatory cytokines would predict the severity of motor symptoms in persons with PD, and that there will be higher levels of peripheral inflammatory cytokine markers in persons with PD when compared to age-matched healthy older adults.

Methods: Twenty-six participants with PD and fourteen healthy older adults completed the study. For participants with PD, the motor section of the Unified Parkinson's Disease Rating Scale (UPDRS) was recorded and scored by two Movement Disorders Neurologists masked to the study. A blood sample was collected from both participants with PD and the healthy older adults. Through the MILLIPLEX® map High Sensitivity Human Cytokine Kit, key inflammation-related markers were analyzed (TNF-, IFN-γ, IL-1β, IL-8, IL-2, IL-7, IL-5, IL-13, IL, 4, IL-10 IL-12p70, GM-CSF, and IL-6).

Results: Results revealed significantly higher levels of IL-6 in persons with PD when compared to healthy older adults ( ​= ​0.005). Moreover, results revealed that higher levels of IL-4 ( ​= ​0.011) and lower levels of IFNγ ( ​= ​0.003) significantly predicted more severe tremor in persons with PD. No other associations between the peripheral inflammation markers and other motor symptoms were observed.

Conclusions: Overall, these results are consistent with a growing body of literature that implicates inflammatory cytokines in the PD, and further suggests that inflammatory cytokines, or lack thereof, may be associated with tremor in persons with PD.

Citing Articles

Potential Biomarkers and Treatment of Neuroinflammation in Parkinson's Disease.

Zhao Z, Fu Q, Guo X, He H, Yang G Actas Esp Psiquiatr. 2025; 53(1):181-188.

PMID: 39801407 PMC: 11726199. DOI: 10.62641/aep.v53i1.1779.


LRRK2 G2019S Mutated iPSC-Derived Endothelial Cells Exhibit Increased α-Synuclein, Mitochondrial Impairment, and Altered Inflammatory Responses.

Sonninen T, Peltonen S, Niskanen J, Hamalainen R, Koistinaho J, Lehtonen S Int J Mol Sci. 2024; 25(23).

PMID: 39684585 PMC: 11641647. DOI: 10.3390/ijms252312874.


ASC specks as a single-molecule fluid biomarker of inflammation in neurodegenerative diseases.

Lobanova E, Zhang Y, Emin D, Brelstaff J, Kahanawita L, Malpetti M Nat Commun. 2024; 15(1):9690.

PMID: 39528447 PMC: 11555386. DOI: 10.1038/s41467-024-53547-0.


Differentiation and regulation of CD4 T cell subsets in Parkinson's disease.

Sun X, Gu R, Bai J Cell Mol Life Sci. 2024; 81(1):352.

PMID: 39153043 PMC: 11335276. DOI: 10.1007/s00018-024-05402-0.


Determining the role of statins in Parkinson's disease risk reduction and disease modification: A comprehensive meta-analysis of 4 million participants' data.

Mady A, Nabil Y, Daoud A, Alnajjar A, Alsalloum T, Marwan M CNS Neurosci Ther. 2024; 30(8):e14888.

PMID: 39097909 PMC: 11298167. DOI: 10.1111/cns.14888.


References
1.
Wijeyekoon R, Kronenberg-Versteeg D, Scott K, Hayat S, Jones J, Clatworthy M . Monocyte Function in Parkinson's Disease and the Impact of Autologous Serum on Phagocytosis. Front Neurol. 2018; 9:870. PMC: 6198066. DOI: 10.3389/fneur.2018.00870. View

2.
Wang J, Yang Q, Sun X, Vesek J, Mosher Z, Vasavada M . MRI evaluation of asymmetry of nigrostriatal damage in the early stage of early-onset Parkinson's disease. Parkinsonism Relat Disord. 2015; 21(6):590-6. DOI: 10.1016/j.parkreldis.2015.03.012. View

3.
Mastrangelo M, Sudol K, Narrow W, Bowers W . Interferon-{gamma} differentially affects Alzheimer's disease pathologies and induces neurogenesis in triple transgenic-AD mice. Am J Pathol. 2009; 175(5):2076-88. PMC: 2774071. DOI: 10.2353/ajpath.2009.090059. View

4.
Sethi K . Levodopa unresponsive symptoms in Parkinson disease. Mov Disord. 2008; 23 Suppl 3:S521-33. DOI: 10.1002/mds.22049. View

5.
Grozdanov V, Bliederhaeuser C, Ruf W, Roth V, Fundel-Clemens K, Zondler L . Inflammatory dysregulation of blood monocytes in Parkinson's disease patients. Acta Neuropathol. 2014; 128(5):651-63. PMC: 4201759. DOI: 10.1007/s00401-014-1345-4. View